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Objective: To compare survival and outcome in patients receiving a mechanical or bioprosthetic heart
valve prosthesis.
Design: Randomised prospective trial.
Setting: Tertiary cardiac centre.
Patients: Between 1975 and 1979, patients were randomised to receive either a Bjork-Shiley or a
porcine prostheses. The mitral valve was replaced in 261 patients, the aortic in 211, and both valves
in 61 patients. Follow up now averages 20 years.
Main outcome measures: Death, reoperation, bleeding, embolism, and endocarditis.
Results: After 20 years there was no difference in survival (Bjork-Shiley v porcine prosthesis (mean
(SEM)): 25.0 (2.7)% v 22.6 (2.7)%, log rank test p = 0.39). Reoperation for valve failure was under-
taken in 91 patients with porcine prostheses and in 22 with Bjork-Shiley prostheses. An analysis com-
bining death and reoperation as end points confirmed that Bjork-Shiley patients had improved survival
with the original prosthesis intact (23.5 (2.6)% v 6.7 (1.6)%, log rank test p < 0.0001); this difference
became apparent after 8–10 years in patients undergoing mitral valve replacement, and after 12–14
years in those undergoing aortic valve replacement. Major bleeding was more common in Bjork-Shiley
patients (40.7 (5.4)% v 27.9 (8.4)% after 20 years, p = 0.008), but there was no significant difference
in major embolism or endocarditis.
Conclusions: Survival with an intact valve is better among patients with the Bjork-Shiley spherical tilt-
ing disc prosthesis than with a porcine prosthesis but there is an attendant increased risk of bleeding.
We have previously reported the results of a ran-domised trial begun in 1975 that compared me-chanical with porcine prostheses for heart valve
replacement. After a median follow up of 12 years we reported
significantly better survival with an intact valve among
patients with the Bjork-Shiley prosthesis, because of the
increased incidence of reoperation for porcine valve failure
seven or more years after implantation. There was a trend
towards improved patient survival after 12 years with the
Bjork-Shiley prosthesis, but this did not reach significance.
The use of the Bjork-Shiley valve carried an attendant
increased risk of bleeding associated with the absolute
requirement for anticoagulant treatment.1 2 We now report on
survival, valve failure, and valve related complications after
extending the follow up period to 20 years.
METHODS
The patients and methods have been described in detail
previously.1 2 In brief, 541 patients undergoing valve replace-
ment in the period from 1975 to 1979 and who were
considered eligible to receive warfarin were randomly
assigned at the time of operation to receive either a mechani-
cal Bjork-Shiley 60° spherical tilting disc valve or a porcine
bioprosthetic valve. The Bjork-Shiley spherical disc valve pre-
ceded the convexo-concave model introduced in 1979, which
was subsequently shown to have an unacceptably high rate of
strut fracture. In all, 261 patients underwent mitral valve
replacement, 211 underwent aortic valve replacement, and 61
had both valves replaced. Eight patients who underwent addi-
tional tricuspid valve replacement were excluded from further
analysis. Of the 533 patients studied, 267 received the
Bjork-Shiley prosthesis. Initially the patients assigned to a
porcine bioprosthesis received a Hancock prosthesis (107
patients), but after January 1977 such patients received a
Carpentier-Edwards prosthesis (159 patients) because of a
substantial cost advantage.
The clinical characteristics of the patients have been
described previously.1 2 The mean (SD) age of the patients at
the time of valve replacement was 53.9 (10.6) years; 54.4
(10.4) years in the Bjork-Shiley group and 53.4 (10.7) years in
the porcine group. The two treatment groups were also
comparable with regard to a large number of other preopera-
tive variables. Overall 296 (56%) of the patients in the study
were female, 40 (7.5%) had had a previous valve replacement,
and fewer than 9% had documented evidence of ischaemic
heart disease. Half of those undergoing single mitral valve
replacement had had a previous mitral valvotomy. All patients
with the Bjork-Shiley prosthesis received warfarin, and those
with a porcine bioprosthesis received warfarin at the
discretion of their cardiologist. Surviving patients have been
followed up as previously described.1 2
Follow up of surviving patients
Since our last report, the 254 surviving patients have been fol-
lowed up a further 545 times. This follow up was at regular
intervals at clinic visits or through mailed questionnaires,
with subsequent clarification of events from the patient, hos-
pital records, or family doctor if necessary. Data regarding
reoperation were obtained from the cardiac surgery database.
All patients enrolled in the study were flagged with the Gen-
eral Register Office for Scotland and a death certificate
obtained following the death, in Scotland, of any patient.
There were six patients lost to follow up during the study
and the remaining survivors were followed up until at least 1
February 1998; the mean duration of follow up was 20.4 years.
Statistical analysis
Statistical analysis was based on the standard methods for
assessing survival data, as previously described.1 2 Analyses
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comparing the two types of porcine valves showed their results
to be very similar and therefore, as before, we present the
results for patients receiving the Bjork-Shiley prosthesis as
compared with those receiving a porcine prosthesis.
RESULTS
Late postoperative deaths
Survival
Of the 533 patients included in our analysis, 46 died within 30
days of their valve replacement operation, and there have been
358 late deaths, including those occurring after reoperation.
Of the 404 deaths, 202 occurred in the group receiving the
Bjork-Shiley prosthesis and 202 in those receiving a porcine
prosthesis. Death was from a non-cardiac cause in 56 patients
(28%) with the Bjork-Shiley prosthesis and in 46 patients
(23%) with a porcine prosthesis.
Analysis of survival
Analysis of the survival of all the patients in the study showed
no significant difference between the Bjork-Shiley and the
porcine prostheses. The trend towards better survival among
patients with a Bjork-Shiley prosthesis seen over 12 years did
not continue when the follow up was extended over 20 years
(table 1, fig 1). There was no significant difference between the
types of prostheses in the subgroups of patients undergoing
aortic valve replacement, mitral valve replacement, or com-
bined aortic valve and mitral valve replacement (table 2).
Late postoperative events
Reoperation
One hundred and thirteen patients (21%) have undergone
reoperation for prosthetic valve replacement—22 with a
Bjork-Shiley valve and 91 with a porcine bioprosthesis (37
with the Hancock valve and 54 with the Carpentier-Edwards
valve). Reoperation was more common in patients with
porcine bioprostheses than in those with a Bjork-Shiley pros-
thesis when all patients were considered together (table 1).
Reoperation was also more common in patients with porcine
bioprostheses when the subgroups of patients who had
undergone single aortic valve, single mitral valve, or combined
mitral valve and aortic valve replacement were considered
separately (table 2).
In this study there were only 98 deaths where a necropsy
was performed, a necropsy rate of 24%. Although sudden
valve failure with the patient dying before a reoperation can
be done is not a common event, the valve failure may go
unrecognised unless a necropsy is performed. We therefore
conducted an analysis in which death or reoperation served
as the end point for an assessment of valve survival. This
analysis showed significantly better survival with the original
prosthesis intact in patients who had undergone a Bjork-
Shiley valve replacement when all patients were considered
together (table 1 and fig 2).
When the subgroups who had undergone single mitral
valve replacement, single aortic valve replacement, or com-
bined aortic and mitral valve replacement were considered
separately there was significantly better valve survival in
patients in whom a Bjork-Shiley valve had been used for sin-
gle mitral valve replacement; the survival curves had clearly
separated after 8–10 years (table 2 and fig 3). For single aortic
valve replacement the survival curves had clearly separated
after 12–14 years (table 2 and fig 3). For combined aortic and
mitral valve replacement the survival curves separated after
8–10 years (table 2).
Overall, 16 patients requiring reoperation died within 30
days of operation (a mortality of 14.2%) and 25 patients died
within one year (a mortality of 22.2%). For the period from the
start of the study to 1987, 30 day mortality after reoperation
was 18.3%, and from 1987 the corresponding 30 day mortality
after reoperation was 9.4%.
Bleeding
There were 175 episodes of bleeding recorded in 127 patients
(24%), including 114 episodes of major bleeding in 87 patients
(16%). The incidence of major bleeding was significantly
higher in the patients with the Bjork-Shiley prosthesis in all
groups with the exception of the group undergoing combined
aortic and mitral valve replacement (tables 1 and 2). The inci-
dence of all episodes of bleeding was significantly higher in
patients with the Bjork-Shiley prosthesis when all patients
were considered together and in the subgroup undergoing
single aortic valve replacement; for the subgroups of patients
undergoing mitral valve replacement and combined aortic and
mitral valve replacement there was no significant difference
(table 2).
The 102 patients with a porcine aortic prosthesis received
warfarin for 23% of the total patient-years of follow up, while
the 132 patients with porcine mitral prostheses received war-
farin for 38% of this period. The proportion of patients with a
porcine prosthesis receiving warfarin increased with time fol-
lowing their operation. At five years 15% of patients with a
porcine aortic prosthesis and 36% of those with a porcine
mitral prosthesis were receiving warfarin; by 15 years this
proportion had risen to 33% and 57%, respectively.
Embolism
A minor embolism was defined as an episode of transient
neurological deficit, amaurosis fugax, limb ischaemia of
Table 1 Actuarial survival and occurrence of valve
related events after 10 and 20 years in patients
receiving a Bjork-Shiley or porcine prosthesis
All patients
p Value*10 years 20 years
Survival
All survivors
Bjork-Shiley valve 58.7 (3.0) 25.0 (2.7) 0.39
Porcine valve 53.6 (3.1) 22.6 (2.7)
Survivors with original prosthesis intact
Bjork-Shiley valve 55.7 (3.1) 23.5 (2.6) <0.0001
Porcine valve 42.6 (3.0) 6.7 (1.6)
Survivors without a major event
Bjork-Shiley valve 47.0 (3.1) 13.8 (2.2) 0.0007
Porcine valve 37.3 (3.0) 4.8 (1.4)
Valve related events
Reoperation
Bjork-Shiley valve 7.1 (1.8) 12.2 (2.5) <0.0001
Porcine valve 27.0 (3.3) 67.8 (5.0)
Bleeding: all episodes
Bjork-Shiley valve 15.3 (2.7) 55.6 (5.5) 0.007
Porcine valve 7.5 (2.2) 43.6 (8.6)
Bleeding: major episodes
Bjork-Shiley valve 11.7 (2.4) 40.7 (5.4) 0.008
Porcine valve 4.9 (1.8) 27.9 (8.4)
Embolism: all episodes
Bjork-Shiley valve 19.4 (2.8) 36.6 (4.6) 0.77
Porcine valve 25.1 (3.3) 37.9 (6.5)
Embolism: major episodes
Bjork-Shiley valve 8.3 (1.9) 13.9 (3.1) 0.68
Porcine valve 9.0 (2.2) 13.6 (4.9)
Endocarditis
Bjork-Shiley valve 3.8 (1.4) 7.5 (2.6) 0.60
Porcine valve 4.6 (1.6) 10.3 (4.6)
Values are % (mean (SEM)).
*p Value from log rank tests, Bjork-Shiley v porcine valves at 20
years.
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sudden onset, or other clinical event that could reasonably be
attributed to embolism. A major embolism was defined as an
embolism resulting in residual neurological deficit, limb
ischaemia requiring surgery, or death.
In all, 158 episodes of embolism were recorded in 121
patients (23%), including 53 episodes of major embolism in 47
patients (9%). There was no difference in the incidence of
major embolism or any embolism between the Bjork-Shiley
valve group and the porcine valve group (tables 1 and 2).
Bacterial endocarditis
Bacterial endocarditis occurred on 32 occasions in 25 patients
(5%), and twice in seven patients. There was no difference in
the incidence of endocarditis between the prosthesis groups
(tables 1 and 2).
All major events
In all, 480 patients have experienced a major event—that is,
death, reoperation, major bleeding, major embolism, or endo-
carditis. These comprised 231 patients with a Bjork-Shiley
prosthesis and 249 with a porcine prosthesis. Analysis of sur-
vival free from all major events showed a significant difference
in favour of the Bjork-Shiley prosthesis when all patients were
considered together (table 1). The subgroup undergoing single
mitral valve replacement not only had a higher incidence of
major events compared with those undergoing single aortic
valve replacement, but there was also a significant difference
in favour of the Bjork-Shiley prosthesis in the group undergo-
ing single mitral valve replacement (table 2, fig 4). For those
undergoing single aortic valve replacement (table 2, fig 4),
there was no significant difference in freedom from all major
events between prostheses.
Functional class
Forty one per cent of the survivors in the group originally
given a porcine prosthesis were in New York Heart Association
functional class III or IV at the end of the study period
compared with 36% of the survivors in the Bjork-Shiley group
(χ2 test for trend: p = 0.26).
DISCUSSION
After a mean follow up period of 20 years in a large prospec-
tive randomised trial we have observed no difference in
survival among patients undergoing valve replacement with
the Bjork-Shiley tilting disc prosthesis as compared with the
Hancock or Carpentier-Edwards porcine prostheses. In our
previous report after a mean follow up period of 12 years we
had observed a trend towards improved survival with the
Bjork-Shiley prosthesis, but this trend did not continue and
with further follow up the survival curves have converged.
Although there was no difference in overall mortality, there
were important differences in morbidity.
The need for reoperation was significantly greater for all
patients who had received a porcine prosthesis. As in our pre-
vious report we considered that there might be confounding
factors to bias the comparison of the failure rates of porcine
Table 2 Actuarial survival and occurrence of valve related events after 10–20 years in patients receiving a Bjork-Shiley
or porcine prosthesis
Aortic valve replacement Mitral valve replacement Aortic + mitral valve replacement
10 Years 20 Years p Value* 10 Years 20 Years p Value* 10 Years 20 Years p Value*
Survival
All survivors
Bjork-Shiley valve 64.0 (4.6) 28.4 (4.4) 0.57 52.7(4.4) 22.4(3.8) 0.41 65.5(8.8) 24.1(8.0) 0.068
Porcine valve 65.7 (4.7) 31.3 (4.7) 46.5(4.4) 18.4(3.6) 43.8(8.8) 11.7(5.9)
Survivors with original prosthesis intact
Bjork-Shiley valve 63.1 (4.6) 27.5 (4.3) 0.025 48.8(4.4) 20.8(3.7) <0.0001 58.6(9.2) 20.7(7.5) 0.002
Porcine valve 58.8 (4.9) 13.7 (3.6) 31.0(4.1) 2.5(1.4) 37.5(8.6) 3.1(3.1)
Survivors without a major event
Bjork-Shiley valve 53.8 (4.8) 15.2 (3.5) 0.34 41.1(4.3) 11.9(3.0) 0.005 48.3(9.3) 17.2(7.0) 0.018
Porcine valve 52.0 (5.0) 8.1 (3.0) 25.6(3.8) 2.5(1.4) 37.5(8.6) 3.1(3.1)
Valve related events
Reoperation
Bjork-Shiley valve 4.2 (2.1) 7.4 (3.0) <0.0001 8.5(2.9) 13.4(3.9) <0.0001 12.8(6.9) 24.2(9.7) 0.003
Porcine valve 11.3 (3.6) 56.2 (8.4) 38.6(5.5) 77.6(6.7) 40.7(10.6) 70.9(11.0)
Bleeding: all episodes
Bjork-Shiley valve 16.3 (4.2) 61.1 ( 7.6) 0.001 14.3(3.9) 53.1(8.2) 0.39 14.9(8.1) 35.0(14.5) 0.71
Porcine valve 5.9 (2.9) 42.4 (12.1) 11.1(4.3) 37.2(10.9) 0.0(0.0) 70.4(24.4)
Bleeding: major episodes
Bjork-Shiley valve 12.2 (3.7) 37.8 (7.1) 0.021 11.6(3.5) 47.3(8.5) 0.044 9.5(6.5) 22.4(13.2) 0.24
Porcine valve 4.2 (2.4) 32.0 (12.6) 6.6(3.1) 9.5(4.1) 0.0(0.0) 70.4(24.4)
Embolism: all episodes
Bjork-Shiley valve 9.8 (3.2) 24.0 (6.2) 0.13 29.5(4.8) 53.4(7.1) 0.32 13.3(7.3) 13.3(7.3) 0.68
Porcine valve 22.6 (4.9) 39.2 (8.8) 28.6(5.1) 32.0(5.9) 18.7(8.8) 18.7(8.8)
Embolism: major episodes
Bjork-Shiley valve 2.0 (1.4) 10.3 (4.9) 0.26 14.2(3.6) 18.3(4.5) 0.19 7.9(5.4) 7.9(5.4) 0.54
Porcine valve 8.9 (3.3) 15.4 (7.0) 10.1(3.4) 10.1(3.4) 4.6(4.4) 4.6(4.4)
Endocarditis
Bjork-Shiley valve 4.8 (2.4) 8.3 (4.1) 0.71 2.3(1.7) 4.5(2.7) 0.38 5.8(5.4) 13.4(9.0) 0.40
Porcine valve 2.2 (1.6) 8.7 (6.5) 7.4(3.4) 7.4(3.4) 4.6(4.4) 28.4(20.9)
Values are % (mean (SEM)).
*p Values from log rank tests: Bjork-Shiley v porcine valves at 20 years.
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and Bjork-Shiley valves. Occasionally a valve may fail
suddenly, causing death before the patient can be brought to
surgery, and as necropsy was rarely done in this study it is
possible that some failures of prosthetic valves went unrecog-
nised. We therefore undertook an analysis with death or reop-
eration as an end point for assessment of valve survival. This
analysis showed that valve survival was significantly better in
patients with the Bjork-Shiley prosthesis in the whole group
and in each of the subgroups undergoing single aortic valve,
single mitral valve, and combined mitral valve and aortic valve
replacement.
In our previous report, at a mean follow up of 12 years,
improved valve survival in patients undergoing single mitral
valve replacement had become apparent at 8–10 years2; in the
current report after a mean follow up of 20 years, significantly
improved valve survival in those undergoing single aortic
valve replacement became apparent after 12–14 years. In the
smaller subgroup of patients undergoing combined mitral
valve and aortic valve replacement, improved valve survival
with the Bjork-Shiley prosthesis became apparent after 8–10
years and became significant with the accumulation of more
prolonged follow up data.
Figure 1 Survival among all
patients. There was no significant
difference between patients receiving
a Bjork-Shiley prosthesis and those
receiving a porcine prosthesis (log
rank test: p = 0.39). The numbers of
surviving patients after each year of
follow up are shown at the bottom of
the figure.
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Figure 2 Survival among all
patients with original prosthesis intact
(that is, survival without reoperation).
Valve survival was significantly better
in the patients with Bjork-Shiley
prostheses (log rank test: p <
0.0001). The numbers of surviving
patients with the original prosthesis
intact are shown at the bottom of the
figure.
100
80
60
40
20
0
Bjork-Shiley
Porcine
201814 16128 10
Years after randomisation
Bjork-Shiley
Pa
tie
nt
s 
su
rv
iv
in
g 
w
ith
 o
rig
in
al
 p
ro
sth
es
is
 in
ta
ct
 (%
)
640 2
4376110 99127161 148173190267 213
112451 3776149 111178192266 208
Porcine
718 Oxenham, Bloomfield, Wheatley, et al
www.heartjnl.com
Non-randomised observational studies with extended peri-
ods of follow up have also reported a high incidence of failure
of porcine prosthetic valves, with failure occurring more com-
monly and earlier in patients undergoing mitral valve replace-
ment than aortic valve replacement.3–5 When reoperation for
valve failure was required in patients in our series with both
aortic and mitral porcine prostheses, the mitral prosthesis was
found to have failed more than twice as often as the aortic
prosthesis—a finding also reported in other studies.6 7
Reoperation for valve failure was associated with substan-
tial mortality: 14% at 30 days and 22% at one year after reop-
eration. Even though the 30 day mortality of 9% in the later
years of follow up was only half of that before 1987, reopera-
tion carried a high risk of death. Our results are comparable
with the UK heart valve registry which reports a 30 day mor-
tality rate for reoperation of 16.6% over the years 1986 to
1997.8 From a single US centre, Akins and colleagues reported
a mortality for reoperation of 6.8% for mitral, 7.8% for aortic,
and 14.3% for double prosthetic valve replacement over the
period 1985 to 1997.9
Bleeding occurred more often in patients receiving the
Bjork-Shiley prosthesis, all of whom received oral anticoagu-
lants. Major bleeding episodes were more common with the
Bjork-Shiley prosthesis in the single aortic valve and single
mitral valve groups, but there was no significant difference in
the group undergoing combined mitral valve and aortic valve
replacement, which involved a smaller number of patients.
When all episodes of bleeding (both major and minor) were
considered, there was a higher incidence of bleeding with the
Bjork-Shiley prosthesis in patients undergoing single aortic
valve replacement but not in those undergoing single mitral
valve replacement. This may reflect the higher proportion of
patients undergoing single mitral valve replacement with a
porcine prosthesis who were also receiving warfarin. With
increasing time from operation a greater proportion of porcine
valve replacement patients received warfarin. This was mainly
because of patient factors such as the development of atrial
fibrillation or chamber enlargement rather than factors
directly related to the prosthetic valve.
The increased risk of bleeding in patients receiving a Bjork-
Shiley prosthesis partly offsets the increased risk of reopera-
tion in those receiving a porcine prosthesis. We found no dif-
ference in the occurrence of embolism or endocarditis
between the groups. Analysis of survival free from a major
event showed a significantly better outcome with the
Bjork-Shiley prosthesis in the group undergoing single mitral
valve and combined aortic valve and mitral valve replacement,
but the difference did not reach significance in the single aor-
tic valve replacement group. The level of anticoagulation
required with the current generation of bileaflet mechanical
prostheses is lower than for the Bjork-Shiley prosthesis10–12 and
the risk of bleeding is reduced, so the relative benefit of
mechanical prostheses may now be even more pronounced.
The Department of Veterans Affairs has carried out a simi-
lar study to our own, starting in 1977 and comparing the
Bjork-Shiley with the Hancock porcine prosthesis in an all
male population of patients undergoing single valve
replacement.13 14 After a follow up period of 15 years Hammer-
meister and colleagues reported significantly improved sur-
vival in patients who had undergone aortic valve replacement
with the Bjork-Shiley prosthesis.15 After 15 years, 34% of those
receiving a Bjork-Shiley prosthesis versus 21% of those receiv-
ing a Hancock bioprosthesis were still alive. As in our study,
Hammermeister and colleagues found no difference in
survival in those patients undergoing mitral valve replace-
ment. The difference in survival in patients who had
undergone aortic valve replacement with the Hancock
bioprosthesis compared with the mechanical valve was, they
found, “probably due to more deaths from primary valve fail-
ure (8 v 0)”. They also found that “almost all of the excess
deaths with bioprosthesis after aortic valve replacement
occurred in the 10 to 15 year time period”. Both an increased
Figure 3 Survival among patients
with original prosthesis intact,
according to site of implantation
(aortic or mitral valve). Valve survival
was significantly better in those
receiving Bjork-Shiley prostheses than
in those receiving porcine prostheses,
both in the group undergoing aortic
valve replacement (log rank test:
p = 0.025) and in the group
undergoing mitral valve replacement
(log rank test: p < 0.0001). The
separation of the survival curves
occurred earlier in those undergoing
mitral valve replacement. The
numbers of surviving patients with the
original prosthesis intact are shown at
the bottom of the figure.
100
80
60
40
20
0
Bjork-Shiley
AVR:
Porcine
201814 16128 10
Years after randomisation
Bjork-Shiley
Mitral valve
replacement
Aortic valve
replacement
Pa
tie
nt
s 
su
rv
iv
in
g 
w
ith
 o
rig
in
al
 p
ro
sth
es
is
 in
ta
ct
 (%
)
640 2
203751 465872 687885109 92
71733 254467 607781102 83
Bjork-Shiley
MVR:
Porcine
193244 405371 637685129 99
3616 102769 398190132 101
Porcine
Twenty year follow up heart valve study 719
www.heartjnl.com
need for reoperation in patients who had undergone aortic
valve replacement with a bioprosthesis and inferior valve sur-
vival after about 10 years compared with the mechanical valve
were also identified in our study. The Veterans Affairs study
enrolled twice as many patients undergoing single aortic valve
replacement as in our study, and all were male. Thus, the
greater statistical power afforded by a larger cohort and the
influence of other patient variables may have operated to pro-
duce the difference in survival seen in the Veterans Affairs
study. Hammermeister and colleagues also reported an
increased risk of bleeding in the Veterans Affairs study in
those patients receiving the Bjork-Shiley prosthesis compared
with those receiving a bioprosthesis. The absolute risks of
bleeding in the Veterans Affairs study were higher than we
observed. This may reflect a higher intensity of anti-
coagulation used in the USA during the major period of the
trial compared with that used in the UK, owing to differences
in the thromboplastins used to standardise the prothrombin
assay.15 16 There was no difference in the incidence of endocar-
ditis or embolism.15 17 Peterseim and colleagues recently
reported a large retrospective study comparing outcomes in
patients undergoing aortic valve replacement; they found no
difference in survival after 10 years of follow up but a signifi-
cantly increased incidence of reoperation in patients receiving
a porcine prosthesis compared with those receiving a St Jude
mechanical prosthesis.18
Our study emphasises the need for prolonged follow up of
patients undergoing valve replacement in order to show
significant differences between treatment groups. Trends
towards improved survival seen after 12 years did not develop
further with prolonged follow up, probably as a result of the
overwhelming effect of patient variables in this aging group of
individuals. However, important differences in valve survival
did become apparent in all treatment groups during this
extended period of follow up.
Recommendations
On the basis of this study, we recommend that patients
undergoing single mitral valve or combined aortic valve and
mitral valve replacement should receive mechanical prosthe-
ses because of their superior durability compared with
bioprostheses. Furthermore many such patients will have, or
will develop, coexisting conditions such as atrial fibrillation
for which anticoagulation is necessary. Patients receiving a
single aortic valve replacement who would be expected to live
10 years or more should receive a mechanical valve unless
anticoagulation treatment is contraindicated. Our results also
have important implications for health care provision,
particularly in the UK where there are long waiting lists for
cardiac surgery. Patients requiring prosthetic valve replace-
ment use scarce cardiac surgery resources. Mechanical valves
have proved to be more durable over several generations of
prostheses19 over prolonged periods of follow up, and their use
should reduce the need for further cardiac surgery in those in
whom they are implanted.
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Figure 4 Survival without major
event according to site of
implantation (aortic or mitral valve).
Survival without major event was
significantly better in patients
undergoing single aortic valve
replacement than in those undergoing
single mitral valve replacement. For
patients undergoing single mitral
valve replacement, survival without
major event was better with
Bjork-Shiley prostheses (log rank test:
p = 0.005) but there was no
significant difference in the aortic
valve replacement group (log rank
test: p = 0.34). The numbers of
patients surviving without event are
shown at the bottom of the figure.
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